July 2 (Reuters) - Celea Therapeutics, linked to PureTech Health, on Thursday completed a $180 million financing round for a late-stage trial of its lung disease drug, deupirfenidone, in patients with ...
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to IPF ...
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's ...
Boston biotech Celea Therapeutics raised $180 million from RA Capital, Leaps by Bayer and others to fund a Phase 3 trial of ...
Analysts are forecasting 200% and 460% returns on these two UK shares! Here's what investors need to know before diving in and buying shares. The post 2 UK shares tipped to more than double my money ...
PureTech Health(NASDAQ:PRTC) reported its second quarter 2025 earnings on Aug. 28, 2025, highlighting a cash balance of just under $320 million at the end of the first half of 2025, a reduction in ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Daphne Zohar, who founded Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results